Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSII Cardiovascular Systems	$20.00	$19.98	$12.26 ▼ $20.57	$843.96M	0.74	765,906 shs	4,300 shs
INO Inovio Pharmaceuticals	$1.94 +7.8%	$1.80	$1.42 ▼ $13.44	$71.15M	1.4	589,390 shs	604,996 shs
LMAT LeMaitre Vascular	$82.46 +2.7%	$84.06	$71.42 ▼ $109.58	$1.86B	0.86	163,418 shs	195,917 shs
SILK Silk Road Medical	$27.49	$27.31	$6.08 ▼ $27.51	$1.12B	1.53	1.20 million shs	N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSII Cardiovascular Systems	0.00%	0.00%	0.00%	0.00%	0.00%
INO Inovio Pharmaceuticals	0.00%	-5.47%	+12.73%	-5.47%	-82.96%
LMAT LeMaitre Vascular	0.00%	+1.91%	-3.16%	-18.53%	+5.35%
SILK Silk Road Medical	0.00%	0.00%	0.00%	0.00%	+30.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CSII Cardiovascular Systems	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	3.6278 of 5 stars	3.3	1.0	0.0	4.3	2.7	0.0	1.3
LMAT LeMaitre Vascular	2.9797 of 5 stars	2.3	1.0	3.3	0.0	3.4	3.3	1.3
SILK Silk Road Medical	0.3218 of 5 stars	0.8	0.0	0.0	4.3	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CSII Cardiovascular Systems	0.00	N/A	N/A	N/A
INO Inovio Pharmaceuticals	2.60	Moderate Buy	$12.20	528.87% Upside
LMAT LeMaitre Vascular	2.63	Moderate Buy	$98.14	19.02% Upside
SILK Silk Road Medical	1.67	Reduce	$27.50	0.04% Upside

Current Analyst Ratings Breakdown

Latest SILK, CSII, LMAT, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/19/2025	INO Inovio Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$6.00 ➝ $5.00
3/19/2025	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
2/28/2025	LMAT LeMaitre Vascular	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $110.00
2/28/2025	LMAT LeMaitre Vascular	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/28/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/13/2025	LMAT LeMaitre Vascular	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$95.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CSII Cardiovascular Systems	$239.84M	3.52	N/A	N/A	$6.12 per share	3.27
INO Inovio Pharmaceuticals	$217.76K	326.72	N/A	N/A	$5.16 per share	0.38
LMAT LeMaitre Vascular	$226.26M	8.23	$1.46 per share	56.52	$13.38 per share	6.16
SILK Silk Road Medical	$177.13M	6.31	N/A	N/A	$3.88 per share	7.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CSII Cardiovascular Systems	-$36.93M	-$0.97	N/A	N/A	N/A	-15.79%	-15.39%	-11.93%	N/A
INO Inovio Pharmaceuticals	-$135.12M	-$3.99	N/A	N/A	N/A	N/A	-118.17%	-83.47%	5/13/2025 (Estimated)
LMAT LeMaitre Vascular	$30.10M	$1.98	45.06	38.00	2.22	19.40%	13.15%	11.47%	N/A
SILK Silk Road Medical	-$55.74M	-$1.37	N/A	N/A	N/A	-29.53%	-37.30%	-21.57%	N/A

Latest SILK, CSII, LMAT, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	N/A	N/A	N/A	$0.01 million	N/A
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
3/18/2025	Q4 2024	INO Inovio Pharmaceuticals	-$0.87	-$0.69	+$0.18	-$0.60	$0.03 million	$0.12 million
2/27/2025	Q4 2024	LMAT LeMaitre Vascular	$0.49	$0.49	N/A	$0.49	$55.99 million	$55.81 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CSII Cardiovascular Systems	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.97%	+13.30%	40.40%	14 Years
SILK Silk Road Medical	N/A	N/A	N/A	N/A	N/A

Latest SILK, CSII, LMAT, and INO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025
2/18/2025	LMAT LeMaitre Vascular	quarterly	$0.20	0.9%	3/13/2025	3/13/2025	3/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CSII Cardiovascular Systems	0.08	6.04	4.92
INO Inovio Pharmaceuticals	N/A	3.88	3.88
LMAT LeMaitre Vascular	N/A	7.74	5.52
SILK Silk Road Medical	0.49	7.63	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CSII Cardiovascular Systems	86.61%
INO Inovio Pharmaceuticals	26.79%
LMAT LeMaitre Vascular	84.64%
SILK Silk Road Medical	N/A

Insider Ownership

Company	Insider Ownership
CSII Cardiovascular Systems	3.80%
INO Inovio Pharmaceuticals	2.30%
LMAT LeMaitre Vascular	10.79%
SILK Silk Road Medical	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CSII Cardiovascular Systems	780	42.20 million	40.59 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	25.45 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.06 million	Optionable
SILK Silk Road Medical	410	40.63 million	37.91 million	Optionable

SILK, CSII, LMAT, and INO Headlines

Recent News About These Companies

Three Andritz spunlace lines for Alear Silk Road

April 25, 2025 | innovationintextiles.com

ANDRITZ To Supply Three Spunlace Lines To Alear Silk Road New Materials, China

April 25, 2025 | textileworld.com

2,200-year-old grave in China contains 'Red Princess of the Silk Road' whose teeth were painted with a toxic substance

March 12, 2025 | msn.com

Xinjiang a front-runner in BRI medical cooperation

March 7, 2025 | chinadaily.com.cn

Endologix Appoints Andrew Davis as Chief Commercial Officer

March 3, 2025 | businesswire.com

China’s Belt and Road Initiative: The art of exploiting threats and opportunities

February 21, 2025 | tehrantimes.com

Boston Scientific ramped up headcount, real estate footprint in 2024

February 21, 2025 | bizjournals.com

Trump pardons Silk Road founder Ross Ulbricht for online drug scheme

January 23, 2025 | reuters.com

Trump pardons Ross Ulbricht, creator of online black market for illegal drugs

January 23, 2025 | msn.com

Trump pardons founder of Silk Road website

January 23, 2025 | msn.com

Silk Road founder Ross Ulbricht went to prison a libertarian hero. Trump just set him free.

January 22, 2025 | msn.com

Trump pardons online drug marketplace Silk Road founder, Austin native Ross Ulbricht

January 22, 2025 | msn.com

Who Is Ross Ulbricht? What To Know About ‘Silk Road’ Drug Marketplace Founder Pardoned By Trump.

January 22, 2025 | msn.com

Trump pardons Ross Ulbricht, founder of online drug market Silk Road

January 22, 2025 | msn.com

Trump Pardons Creator of Silk Road Drug Marketplace

January 22, 2025 | nytimes.com

Chinese, Pakistani firms sign $250m MoUs

January 19, 2025 | tribune.com.pk

MoUs worth $250m signed with Chinese medical companies

January 19, 2025 | dawn.com

Pakistani, Chinese companies ink $250mn MoUs to boost medical sector

January 18, 2025 | brecorder.com

Pakistani, Chinese companies ink $250 million MoUs to boost medical sector

January 18, 2025 | business-standard.com

Chinese, Pakistani companies reach $250 mln MoUs on medical equipment

January 18, 2025 | app.com.pk

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILK, CSII, LMAT, and INO Company Descriptions

Cardiovascular Systems NASDAQ:CSII

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Inovio Pharmaceuticals NASDAQ:INO

$1.94 +0.14 (+7.78%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 -0.02 (-0.82%)

As of 07:59 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

LeMaitre Vascular NASDAQ:LMAT

$82.46 +2.20 (+2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$82.61 +0.15 (+0.18%)

As of 04:20 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Silk Road Medical NASDAQ:SILK

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time